Expert review of respiratory medicine最新文献_第6页

Advances in lung cancer surgery: the role of segmentectomy in early-stage management. 肺癌手术的进展：分段切除术在早期治疗中的作用。

Expert review of respiratory medicine Pub Date : 2024-09-01 Epub Date: 2024-03-08 DOI: 10.1080/17476348.2024.2324083

Luca Bertolaccini, Monica Casiraghi, Clarissa Uslenghi, Cristina Diotti, Antonio Mazzella, Giovanni Caffarena, Lorenzo Spaggiari

引用次数: 0

New methods to detect bacterial or viral infections in patients with chronic obstructive pulmonary disease. 检测慢性阻塞性肺病患者细菌或病毒感染的新方法。

Expert review of respiratory medicine Pub Date : 2024-09-01 Epub Date: 2024-08-29 DOI: 10.1080/17476348.2024.2396413

John C Hu, Sanjay Sethi

{"title":"New methods to detect bacterial or viral infections in patients with chronic obstructive pulmonary disease.","authors":"John C Hu, Sanjay Sethi","doi":"10.1080/17476348.2024.2396413","DOIUrl":"10.1080/17476348.2024.2396413","url":null,"abstract":"Introduction: Patients with chronic obstructive pulmonary disease (COPD) are frequently colonized and infected by respiratory pathogens. Identifying these infectious etiologies is critical for understanding the microbial dynamics of COPD and for the appropriate use of antimicrobials during exacerbations.Areas covered: Traditional methods, such as bacterial and viral cultures, have been standard in diagnosing respiratory infections. However, these methods have significant limitations, including lack of sensitivity and prolonged turnaround time. Modern molecular approaches offer rapid, sensitive, and specific detection, though they also come with their own challenges. This review explores and evaluates the clinical utility of the latest advancements in detecting bacterial and viral respiratory infections in COPD, encompassing molecular techniques, biomarkers, and emerging technologies.Expert opinion: In the evolving landscape of COPD management, integrating molecular diagnostics and emerging technologies holds great promise. The enhanced sensitivity of molecular techniques has significantly advanced our understanding of the role of microbes in COPD. However, many of these technologies have primarily been developed for pneumonia diagnosis or research applications, and their clinical utility in managing COPD requires further evaluation.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"693-707"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142038027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming resistance in small-cell lung cancer. 克服小细胞肺癌的抗药性。

Expert review of respiratory medicine Pub Date : 2024-08-01 Epub Date: 2024-08-11 DOI: 10.1080/17476348.2024.2388288

Gerhard Hamilton, Maximilian J Hochmair, Sandra Stickler

{"title":"Overcoming resistance in small-cell lung cancer.","authors":"Gerhard Hamilton, Maximilian J Hochmair, Sandra Stickler","doi":"10.1080/17476348.2024.2388288","DOIUrl":"10.1080/17476348.2024.2388288","url":null,"abstract":"Introduction: Small-cell lung cancer (SCLC) accounts for 15% of lung cancers and has a dismal prognosis due to early dissemination and acquired chemoresistance. The initial good response to chemotherapy is followed by refractory relapses within 1-2 years. Mechanisms leading to chemoresistance are not clear and progress is poor.Areas covered: This article reviews the current evidence of the resistance of SCLCs at the cellular level including alteration of key proteins and the possible presence of cancer stem cells (CSCs). Without compelling evidence for cellular mechanisms and clinical failures of novel approaches, the study of SCLC has advanced to the role of 3D tumor cell aggregates in chemoresistance.Expert opinion: The scarcity of viable tumor specimen from relapsed SCLC patients has hampered the investigations of acquired chemoresistance but a panel of nine SCLC circulating tumor cell (CTC) cell lines have revealed characteristics of SCLC in the advanced refractory states. The chemoresistance of relapsed SCLC seems to be linked to the spontaneous formation of large spheroids, termed tumorospheres, which contain resistant quiescent and hypoxic cells shielded by a physical barrier. So far, drugs to tackle large tumor spheroids are in preclinical and early clinical development.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"569-580"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imagining the severe asthma decision trees of the future. 畅想未来的重症哮喘决策树

Expert review of respiratory medicine Pub Date : 2024-08-01 Epub Date: 2024-08-20 DOI: 10.1080/17476348.2024.2390987

Arnaud Bourdin, Phil Bardin, Pascal Chanez

{"title":"Imagining the severe asthma decision trees of the future.","authors":"Arnaud Bourdin, Phil Bardin, Pascal Chanez","doi":"10.1080/17476348.2024.2390987","DOIUrl":"10.1080/17476348.2024.2390987","url":null,"abstract":"Introduction: There are no validated decision-making algorithms concerning severe asthma (SA) management. Future risks are crucial factors and can be derived from SA trajectories.Areas covered: The future severe asthma-decision trees should revisit current knowledge and gaps. A focused literature search has been conducted.Expert opinion: Asthma severity is currently defined a priori, thereby precluding a role for early interventions aiming to prevent outcomes such as exacerbations (systemic corticosteroids exposure) and lung function decline. Asthma 'at-risk' might represent the ultimate paradigm but merits longitudinal studies considering modern interventions. Real exacerbations, severe airway hyperresponsiveness, excessive T2-related biomarkers, noxious environments and patient behaviors, harms of OCS and high-doses inhaled corticosteroids (ICS), and low adherence-to-effectiveness ratios of ICS-containing inhalers are predictors of future risks. New tools such as imaging, genetic, and epigenetic signatures should be used. Logical and numerical artificial intelligence may be used to generate a consistent risk score. A pragmatic definition of response to treatments will allow development of a validated and applicable algorithm. Biologics have the best potential to minimize the risks, but cost remains an issue. We propose a simplified six-step algorithm for decision-making that is ultimately aiming to achieve asthma remission.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"561-567"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141908628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short-term effects of announcing spirometric lung-age on smokers' attitudes: results from a Tunisian real-life pilot study. 公布肺活量对吸烟者态度的短期影响：突尼斯一项真实试点研究的结果。

Expert review of respiratory medicine Pub Date : 2024-08-01 Epub Date: 2024-08-18 DOI: 10.1080/17476348.2024.2390992

Soumaya Khaldi, Khansa Derbel, Ines Ghannouchi, Fatma Guezguez, Amani Sayhi, Wafa Benzarti, Balsam Barkous, Salsabil Bouafia, Fatma Zahra Dabbebi, Emna Charfedi, Helmi Ben Saad

{"title":"Short-term effects of announcing spirometric lung-age on smokers' attitudes: results from a Tunisian real-life pilot study.","authors":"Soumaya Khaldi, Khansa Derbel, Ines Ghannouchi, Fatma Guezguez, Amani Sayhi, Wafa Benzarti, Balsam Barkous, Salsabil Bouafia, Fatma Zahra Dabbebi, Emna Charfedi, Helmi Ben Saad","doi":"10.1080/17476348.2024.2390992","DOIUrl":"10.1080/17476348.2024.2390992","url":null,"abstract":"Background: To determine the effects of informing smokers of their spirometric lung-age (SLA) on smoking cessation (SC) rates and tobacco consumption.Research design and methods: An interventional study was conducted in real-life through a humanitarian event led by the Red Crescent on 9 January 2022, in Hammam-Sousse (Sousse, Tunisia). The study comprised four steps: i) Medical questionnaire (general questionnaire, Fagerström test for cigarette dependence, SC motivation questionnaire); ii) Measurement of spirometric data; iii) SLA estimation and its announcement to participants; and iv) Self-reported evaluation of smoking behavior three months later through telephonic recall. Smokers were divided into groups (nondependent vs. dependent groups and insufficient/moderate motivation vs. high/very high motivation groups) and categories (ceased smoking, reduced consumption, maintained stable or increased consumption).Results: Fifty-two smokers were included (94% were males). Three months after the event, i) 9 (17%) smokers ceased smoking, ii) 39 (75%) smokers reduced their daily smoking consumption by 12 ± 8 cigarettes/day, and iii) 4 (8%) smokers maintained stable (n = 3) or increased (n = 1) consumption.Conclusions: Informing smokers of their SLA led 92% of them to cease smoking or reduce their consumption. Announcing SLA could be an effective motivational tool and an easy-to-understand concept to help smokers cease their habit.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"655-668"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141908629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials. 安思芬特林对中重度慢性阻塞性肺病患者呼吸困难的影响：ENHANCE 试验的汇总分析。

Expert review of respiratory medicine Pub Date : 2024-08-01 Epub Date: 2024-08-08 DOI: 10.1080/17476348.2024.2389960

Donald A Mahler, Surya P Bhatt, Tara Rheault, Daniel Reyner, Thomas Bengtsson, Amy Dixon, Kathleen Rickard, Dave Singh

{"title":"Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials.","authors":"Donald A Mahler, Surya P Bhatt, Tara Rheault, Daniel Reyner, Thomas Bengtsson, Amy Dixon, Kathleen Rickard, Dave Singh","doi":"10.1080/17476348.2024.2389960","DOIUrl":"10.1080/17476348.2024.2389960","url":null,"abstract":"Background: Dyspnea is a critical component of chronic obstructive pulmonary disease (COPD). We report the effect of ensifentrine, a novel PDE3/PDE4 inhibitor, on dyspnea using pooled data from the Phase 3 ENHANCE-1/2 trials.Methods: The pooled population (ensifentrine, n = 975; placebo, n = 574) included patients aged 40-80 years with post-bronchodilator FEV1/FVC <0.7, FEV1 30-70% predicted, mMRC Dyspnea Scale score ≥2, and a smoking history ≥10 pack-years. Patients taking dual LAMA/LABA or LAMA/LABA/ICS triple therapy were excluded. Dyspnea measures included the Transition Dyspnea Index (TDI), Evaluating Respiratory Symptoms (E-RS), and rescue medication use.Results: After 24 weeks, ensifentrine significantly improved TDI scores (least-squares mean difference, 0.97; 95% CI, 0.64, 1.30; p < 0.001) and across all TDI subdomains. Ensifentrine-treated patients were more likely to be TDI responders at week 24 (p < 0.001), which was consistent across clinically relevant subgroups. Ensifentrine-treated patients had improved E-RS breathlessness subdomain scores (p = 0.053) and reduced rescue medication use (p = 0.002).Conclusion: Ensifentrine produced clinically meaningful improvements in multiple dyspnea measures in patients with symptomatic, moderate-to-severe COPD. A limitation of this study was the exclusion of patients taking dual LAMA/LABA and LAMA/LABA/ICS triple therapy.Clinical trial registration: www.clinicaltrials.gov identifiers are ENHANCE-1: NCT04535986; ENHANCE-2: NCT04542057.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"645-654"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141895015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of bronchoscopic lung volume reduction for chronic obstructive pulmonary disease: a systematic review and network meta-analysis. 支气管镜肺容积缩小术治疗慢性阻塞性肺病的有效性和安全性：系统综述和网络荟萃分析。

Expert review of respiratory medicine Pub Date : 2024-08-01 Epub Date: 2024-08-08 DOI: 10.1080/17476348.2024.2388293

Ranran Zhang, Ziwen Zheng, Yiding Bian, Mingming Deng, Felix F J Herth, Gang Hou

{"title":"Efficacy and safety of bronchoscopic lung volume reduction for chronic obstructive pulmonary disease: a systematic review and network meta-analysis.","authors":"Ranran Zhang, Ziwen Zheng, Yiding Bian, Mingming Deng, Felix F J Herth, Gang Hou","doi":"10.1080/17476348.2024.2388293","DOIUrl":"10.1080/17476348.2024.2388293","url":null,"abstract":"Background: Various bronchoscopic lung volume reduction (BLVR) methods have been developed to treat chronic obstructive pulmonary disease (COPD). The efficacy and safety of these interventions remain unclear. This study assessed the efficacy and safety of various BLVR interventions in COPD patients.Methods: PubMed and Embase were searched from inception to 21 October 2023. The primary outcomes assessed included the 6-min walking distance (6MWD), St. George Respiratory Questionnaire (SGRQ) score, lung function, and adverse events (AE). A frequentist approach with a random-effects model was used for a network meta-analysis.Results: Twelve randomized controlled trials (RCTs) with 1646 patients were included in this meta-analysis. Patients treated with an endobronchial valve (EBV) achieved a minimum clinically important difference (MCID) in 6MWD and SGRQ at 6 months. Patients treated with coils achieved MCID in the SGRQ score at 12 months. Patients with aspiration valve system and bronchoscopic thermal vapor ablation (BTVA) achieved MCID in the SGRQ score at 6 months.Conclusions: In COPD patients, EBV should be considered first, while being wary of pneumothorax. Coil and BTVA are potential therapeutic alternatives. Although BTVA demonstrates a safer procedural profile than coils, additional studies are imperative to clarify its efficacy.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"631-644"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141880021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current perspective on e-cigarette use and respiratory outcomes: mechanisms and messaging. 电子烟使用与呼吸系统变量的当前视角：机制与信息传递。

Expert review of respiratory medicine Pub Date : 2024-08-01 Epub Date: 2024-08-11 DOI: 10.1080/17476348.2024.2387090

Thomas A Wills, Wasim Maziak, Taghrid Asfar, Simanta Roy

{"title":"Current perspective on e-cigarette use and respiratory outcomes: mechanisms and messaging.","authors":"Thomas A Wills, Wasim Maziak, Taghrid Asfar, Simanta Roy","doi":"10.1080/17476348.2024.2387090","DOIUrl":"10.1080/17476348.2024.2387090","url":null,"abstract":"Introduction: There has been an increasing amount of research on the consequences of e-cigarette use for respiratory outcomes, which is significant for public health and respiratory medicine. We discuss recent findings and lay out implications for prevention and treatment.Areas covered: Based on literature searches using several databases (PubMed, Web of Science, Google Scholar) for keywords, including synonyms, 'e-cigarettes,' with 'pulmonary function,' 'oxidative stress,' and 'inflammation,' we review studies on acute effects of e-cigarette use for measures of pulmonary function and discuss selected laboratory studies on mechanisms of effect, focusing on processes with known relation to respiratory disease; oxidative stress and inflammation. We discuss available studies that have tested the effectiveness of communication strategies for prevention of e-cigarette use oriented to different audiences, including nonsmoking adolescents and adult smokers.Expert opinion: We conclude that the evidence presents a mixed picture. Evidence is found for adverse consequences of e-cigarette use on measures of lung function and two disease-related biological processes, sometimes but not always less than for cigarette smoking. How to best communicate these results to a complex audience of users, from younger susceptible adolescents to long-term adult smokers interested in quitting, is a question of significant interest and empirically validated communication strategies are greatly needed.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"597-609"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving diagnostic strategies in bronchoscopy for peripheral pulmonary lesions. 改进支气管镜检查周围肺部病变的诊断策略。

Expert review of respiratory medicine Pub Date : 2024-08-01 Epub Date: 2024-08-11 DOI: 10.1080/17476348.2024.2387089

Yuji Matsumoto, Sze Shyang Kho, Hideaki Furuse

{"title":"Improving diagnostic strategies in bronchoscopy for peripheral pulmonary lesions.","authors":"Yuji Matsumoto, Sze Shyang Kho, Hideaki Furuse","doi":"10.1080/17476348.2024.2387089","DOIUrl":"10.1080/17476348.2024.2387089","url":null,"abstract":"Introduction: In the past two decades, bronchoscopy of peripheral pulmonary lesions (PPLs) has improved its diagnostic yield due to the combination of various instruments and devices. Meanwhile, the application is complex and intertwined.Areas covered: This review article outlines strategies in diagnostic bronchoscopy for PPLs. We summarize the utility and evidence of key instruments and devices based on the results of clinical trials. Future perspectives of bronchoscopy for PPLs are also discussed.Expert opinion: The accuracy of reaching PPLs by bronchoscopy has improved significantly with the introduction of combined instruments such as navigation, radial endobronchial ultrasound, digital tomosynthesis, and cone-beam computed tomography. It has been accelerated with the advent of approach tools such as newer ultrathin bronchoscopes and robotic-assisted bronchoscopy. In addition, needle aspiration and cryobiopsy provide further diagnostic opportunities beyond forceps biopsy. Rapid on-site evaluation may also play an important role in decision making during the procedures. As a result, the diagnostic yield of bronchoscopy for PPLs has improved to a level comparable to that of transthoracic needle biopsy. The techniques and technologies developed in the diagnosis will be carried over to the next step in the transbronchial treatment of PPLs in the future.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"581-595"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A clinician's guide to single vs multiple inhaler therapy for COPD. 慢性阻塞性肺病单吸入器疗法与多吸入器疗法的临床医师指南。

Expert review of respiratory medicine Pub Date : 2024-07-01 Epub Date: 2024-07-27 DOI: 10.1080/17476348.2024.2384702

Mario Cazzola, Josuel Ora, Mauro Maniscalco, Paola Rogliani

{"title":"A clinician's guide to single vs multiple inhaler therapy for COPD.","authors":"Mario Cazzola, Josuel Ora, Mauro Maniscalco, Paola Rogliani","doi":"10.1080/17476348.2024.2384702","DOIUrl":"10.1080/17476348.2024.2384702","url":null,"abstract":"Introduction: In the management of chronic obstructive pulmonary disease (COPD), inhalation therapy plays a pivotal role. However, clinicians often face the dilemma of choosing between single and multiple inhaler therapies for their patients. This choice is critical because it can affect treatment efficacy, patient adherence, and overall disease management.Areas covered: This article examines the advantages and factors to be taken into consideration when selecting between single and multiple inhaler therapies for COPD.Expert opinion: Both single and multiple inhaler therapies must be considered in COPD management. While single inhaler therapy offers simplicity and convenience, multiple inhaler therapy provides greater flexibility and customization. Clinicians must carefully evaluate individual patient needs and preferences to determine the most appropriate inhaler therapy regimen. Through personalized treatment approaches and shared decision-making, clinicians can optimize COPD management and improve patient well-being. Nevertheless, further research is required to compare the effectiveness of single versus multiple inhaler strategies through rigorous clinical trials, free from industry bias, to determine the optimal inhaler strategy. Smart inhaler technology appears to have the potential to enhance adherence and personalized management, but the relative merits of smart inhalers in single inhaler regimens versus multiple inhaler regimens remain to be determined.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"457-468"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0